1.64
price down icon17.59%   -0.35
after-market 시간 외 거래: 1.64
loading
전일 마감가:
$1.99
열려 있는:
$2.01
하루 거래량:
16.05M
Relative Volume:
38.96
시가총액:
$59.88M
수익:
-
순이익/손실:
$-69.00M
주가수익비율:
-0.5899
EPS:
-2.78
순현금흐름:
$-55.26M
1주 성능:
-9.39%
1개월 성능:
-69.57%
6개월 성능:
-79.40%
1년 성능:
-80.64%
1일 변동 폭
Value
$1.61
$2.0836
1주일 범위
Value
$1.61
$2.12
52주 변동 폭
Value
$1.30
$10.29

Acrivon Therapeutics Inc Stock (ACRV) Company Profile

Name
명칭
Acrivon Therapeutics Inc
Name
전화
617-207-8979
Name
주소
480 ARSENAL WAY, SUITE 100, WATERTOWN
Name
직원
78
Name
트위터
Name
다음 수익 날짜
2025-03-26
Name
최신 SEC 제출 서류
Name
ACRV's Discussions on Twitter

ACRV을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ACRV
Acrivon Therapeutics Inc
1.64 59.88M 0 -69.00M -55.26M -2.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-01-31 개시 KeyBanc Capital Markets Overweight
2024-09-16 업그레이드 Ladenburg Thalmann Neutral → Buy
2024-04-29 다운그레이드 Ladenburg Thalmann Buy → Neutral
2024-03-01 개시 JMP Securities Mkt Outperform
2023-12-15 재개 Jefferies Buy
2023-10-05 개시 Maxim Group Buy
2023-06-02 개시 Oppenheimer Outperform
2023-05-08 개시 BMO Capital Markets Outperform
2023-04-27 개시 Ladenburg Thalmann Buy
2023-04-20 개시 H.C. Wainwright Buy
2022-12-12 개시 Cowen Outperform
2022-12-12 개시 Jefferies Buy
2022-12-12 개시 Piper Sandler Overweight
모두보기

Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스

pulisher
04:32 AM

ACRV’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

04:32 AM
pulisher
12:01 PM

Understanding ACRV stock ratios for better investment decisions - uspostnews.com

12:01 PM
pulisher
08:02 AM

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 - GlobeNewswire

08:02 AM
pulisher
08:00 AM

Breakthrough Cancer Drug ACR-2316 Achieves 25% Tumor Reduction with Zero Safety Issues in Phase 1 Trial - Stock Titan

08:00 AM
pulisher
Apr 23, 2025

(ACRV) On The My Stocks Page - news.stocktradersdaily.com

Apr 23, 2025
pulisher
Apr 22, 2025

April 2025's Standout Penny Stocks - simplywall.st

Apr 22, 2025
pulisher
Apr 20, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 21.4% in March - Defense World

Apr 20, 2025
pulisher
Apr 14, 2025

Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) - NewsBreak: Local News & Alerts

Apr 14, 2025
pulisher
Apr 08, 2025

Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal moment By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Acrivon Therapeutics’ SWOT analysis: oncology innovator’s stock faces pivotal moment - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal moment - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.17 Average Price Target from Analysts - Defense World

Apr 08, 2025
pulisher
Apr 07, 2025

Acrivon Therapeutics Reports Progress in Cancer Drug Development - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

Acrivon Therapeutics Appoints Mansoor Raza Mirza, M.D., as Chief Medical Officer - citybiz

Apr 07, 2025
pulisher
Apr 07, 2025

Acrivon appoints new chief medical officer to advance cancer trials By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

Acrivon Therapeutics Appoints Mansoor Mirza as Medical Chief - marketscreener.com

Apr 07, 2025
pulisher
Apr 07, 2025

Acrivon appoints new chief medical officer to advance cancer trials - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Acrivon Therapeutics Appoints New Chief Medical Officer - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

Acrivon Therapeutics Appoints World-Renowned Oncology Key - GlobeNewswire

Apr 07, 2025
pulisher
Mar 29, 2025

Q1 Earnings Forecast for ACRV Issued By HC Wainwright - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Acrivon Therapeutics (NASDAQ:ACRV) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Contrast - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

H.C. Wainwright maintains Acrivon stock Buy rating, $19 target By Investing.com - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

H.C. Wainwright maintains Acrivon stock Buy rating, $19 target - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

HC Wainwright Has Lowered Expectations for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

FY2029 Earnings Estimate for ACRV Issued By HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Cantor Fitzgerald Reaffirms “Overweight” Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c) - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

Acrivon Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 27, 2025

Acrivon narrows focus for ACR-368 in endometrial cancer - BioWorld MedTech

Mar 27, 2025
pulisher
Mar 27, 2025

JMP maintains Acrivon stock with $17 target following update By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 26, 2025

Acrivon Therapeutics stock target cut to $19 by H.C. Wainwright - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Nasdaq Down 1%; Dollar Tree To Sell Family Dollar Business For $1 Billion - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer - Endpoints News

Mar 26, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Acrivon stock By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Acrivon stock - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

JMP maintains Acrivon stock with $17 target following update - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Wednesday Sector Laggards: Biotechnology, Semiconductors - Nasdaq

Mar 26, 2025
pulisher
Mar 25, 2025

Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Citizens JMP reiterates Acrivon stock with $17 target By Investing.com - Investing.com South Africa

Mar 25, 2025

Acrivon Therapeutics Inc (ACRV) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
자본화:     |  볼륨(24시간):